Perceptive Advisors LLC acquired a new position in shares of Seres Therapeutics Inc (NASDAQ:MCRB) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 135,000 shares of the biotechnology company’s stock, valued at approximately $2,165,000. Perceptive Advisors LLC owned approximately 0.33% of Seres Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently bought and sold shares of MCRB. Voya Investment Management LLC bought a new position in shares of Seres Therapeutics during the second quarter worth about $114,000. Advisor Group Inc. grew its holdings in shares of Seres Therapeutics by 100.7% during the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock worth $160,000 after buying an additional 7,050 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Seres Therapeutics during the second quarter worth about $169,000. Aperio Group LLC bought a new position in shares of Seres Therapeutics during the third quarter worth about $191,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Seres Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock worth $206,000 after buying an additional 2,410 shares in the last quarter. Institutional investors and hedge funds own 77.83% of the company’s stock.
Seres Therapeutics Inc (MCRB) opened at $10.20 on Monday. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics Inc has a one year low of $8.85 and a one year high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. During the same period in the previous year, the company posted ($0.46) EPS. The firm’s revenue for the quarter was up 76.9% compared to the same quarter last year. research analysts predict that Seres Therapeutics Inc will post -2.33 earnings per share for the current fiscal year.
A number of research firms recently issued reports on MCRB. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. ValuEngine downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Citigroup assumed coverage on Seres Therapeutics in a research note on Thursday, October 12th. They issued a “positive” rating and a $19.00 price target for the company. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, October 2nd. Finally, Oppenheimer assumed coverage on Seres Therapeutics in a research note on Thursday, October 12th. They issued an “outperform” rating and a $19.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.00.
WARNING: “Perceptive Advisors LLC Invests $2.17 Million in Seres Therapeutics Inc (MCRB)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/12/11/perceptive-advisors-llc-invests-2-17-million-in-seres-therapeutics-inc-mcrb.html.
Seres Therapeutics Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics Inc (NASDAQ:MCRB).
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.